|
FY2018
12 months to Dec 31, 2018
|
FY2017
12 months to Dec 31, 2017
|
FY2016
12 months to Dec 31, 2016
|
FY2015
12 months to Dec 31, 2015
|
FY2014
12 months to Dec 31, 2014
|
|
|---|---|---|---|---|---|
| Net income (loss) | |||||
| Cash flows from operating activities: | |||||
| Net (loss) income | |||||
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||||
| Depreciation and amortization expense | |||||
| Provision for bad debts and product returns | |||||
| Provision for inventory write-downs | |||||
| Amortization of deferred revenue | |||||
| Deferred income tax provision | |||||
| Stock-based compensation | |||||
| Asset impairment and abandonments | |||||
| Cardiothoracic closure business divestiture contingency consideration | |||||
| Gain on cardiothoracic closure business divestiture | |||||
| Other | |||||
| Change in assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Accounts payable | |||||
| Deferred revenue | |||||
| Other operating assets and liabilities | |||||
| Net cash provided by operating activities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property, plant and equipment | |||||
| Patent and acquired intangible asset costs | |||||
| Proceeds from sale of building | |||||
| Acquisition of Zyga Technology | |||||
| Cardiothoracic closure business divestiture | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from exercise of common stock options | |||||
| Proceeds from long-term obligations | |||||
| Net (payments) proceeds from short-term obligations | |||||
| Payments on long-term obligations | |||||
| Other financing activities | |||||
| Net cash provided by (used in) financing activities | |||||
| Effect of exchange rate changes on cash and cash equivalents | |||||
| Net (decrease) increase in cash and cash equivalents | |||||
| Cash and cash equivalents, beginning of period | |||||
| Cash and cash equivalents, end of period | |||||
| Supplemental cash flow disclosure: | |||||
| Cash paid for interest | |||||
| Cash paid for income taxes, net of refunds | |||||
| Non-cash acquisition of property, plant and equipment | |||||
| Receivable for executive stock option exercise | |||||
| Stock-based compensation related to sale of CT business | |||||
| Change in accrual for dividend payable | |||||
Loading...